Primary Therapy for Intermediate- and High-Risk Disease
What would be your preferred form of radiation therapy when treating a 65-year-old man with locally advanced, high-risk prostate cancer?
What would be your preferred form of radiation therapy when treating a 65-year-old man with locally advanced, high-risk prostate cancer?
Would you combine this with hormone therapy?
In general, when treating a 65-year-old man with locally advanced, high-risk prostate cancer, which of the following do you consider to be the optimal sequence and duration of androgen deprivation therapy (ADT)?
In general, when treating a 65-year-old man with locally advanced, high-risk prostate cancer, which of the following do you consider to be the optimal sequence and duration of androgen deprivation therapy (ADT)?
What is the total duration of hormone therapy you recommend prior to surgery?
In general, when you use hormonal therapy with radiation therapy, what is the total duration of hormone therapy you recommend (before, during and/or after radiation therapy)?
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 1: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 2: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
Case 3: Clinically localized prostate cancer
I routinely consider the following in recommendations about whether to biopsy versus clinically follow patients
Approximately what percent of your patients on androgen deprivation in your practice have experienced a bone fracture?
Approximately what percent of your patients on androgen deprivation in your practice have experienced a bone fracture?
Patients receiving an LHRH agonist for any reason or duration should have a baseline bone mineral density test.
Patients receiving an LHRH agonist for any reason or duration should have a baseline bone mineral density test.
Patients receiving ongoing hormone therapy should have serial bone mineral density tests performed to assess for significant change.
Patients receiving ongoing hormone therapy should have serial bone mineral density tests performed to assess for significant change.
How many cores do you usually take when you first biopsy the prostate in a patient with a PSA elevation?
Have you ever used bicalutamide 150 mg either as
adjuvant monotherapy or concurrent with radiation therapy
?
Have you ever used bicalutamide 150 mg as
monotherapy
in patients with clinically localized prostate cancer?
In general, all patients with localized prostate cancer should have a consultation with a medical oncologist at some point in the course of their decision-making or treatment.
In general, all patients with localized prostate cancer should have a consultation with a medical oncologist at some point in the course of their decision-making or treatment.
A 57-year-old man presenting with a PSA level of 6.3 ng/mL (compared to 3.2 ng/mL one year prior) was diagnosed with prostate cancer and underwent an RRP one month ago. His pathology report shows a Gleason Score of 9 (5 + 4), right seminal vesicle involvement and a positive surgical margin. Of nodes, 0/5 on the right and 0/5 on the left are positive for metastasis. The
standard of care
for this patient is as follows
A 57-year-old man presenting with a PSA level of 6.3 ng/mL (compared to 3.2 ng/mL one year prior) was diagnosed with prostate cancer and underwent an RRP one month ago. His pathology report shows a Gleason Score of 9 (5 + 4), right seminal vesicle involvement and a positive surgical margin. Of nodes, 0/5 on the right and 0/5 on the left are positive for metastasis. The
standard of care
for this patient is as follows
My recommended therapy
for this case is
My recommended therapy
for this case is
Men with very high-risk disease after radical prostatectomy should be informed about the possibility of receiving
Men with very high-risk disease after radical prostatectomy should be informed about the possibility of receiving
Men with very high-risk disease after radical prostatectomy should be informed about the possibility of receiving
Men with very high-risk disease after radical prostatectomy should be informed about the possibility of receiving
Men with very high-risk disease after radical prostatectomy should be informed about the possibility of receiving
Men with very high-risk disease after radical prostatectomy should be informed about the possibility of receiving
If you had prostate cancer and were eligible to participate in SWOG-S9921 (MAB alone or with mitoxantrone/ prednisone for patients at high risk after RP), how likely would you be to enter the study?
If you had prostate cancer and were eligible to participate in SWOG-S9921 (MAB alone or with mitoxantrone/ prednisone for patients at high risk after RP), how likely would you be to enter the study?
If you had prostate cancer and were eligible to participate in NCT00132301 (“standard of care” versus docetaxel/ prednisone added to “standard of care” for patients at high risk after RP; standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse), how likely is it that you would enter the study?
If you had prostate cancer and were eligible to participate in NCT00132301 (“standard of care” versus docetaxel/ prednisone added to “standard of care” for patients at high risk after RP; standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse), how likely is it that you would enter the study?
Clinical trials will eventually demonstrate that chemotherapy as adjuvant treatment after radical prostatectomy or radiation therapy is effective in reducing the rate of PSA relapse and clinical progression.
Clinical trials will eventually demonstrate that chemotherapy as adjuvant treatment after radical prostatectomy or radiation therapy is effective in reducing the rate of PSA relapse and clinical progression.
How likely would you be to recommend that a patient at high risk for recurrence following radical prostatectomy be randomly assigned to either chemotherapy or no chemotherapy (with or without hormone therapy) in a clinical trial?
How likely would you be to recommend that a patient at high risk for recurrence following radical prostatectomy be randomly assigned to either chemotherapy or no chemotherapy (with or without hormone therapy) in a clinical trial?
